Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab mafodotin combinations in relapsed or refractory multiple myeloma
2017-004689-93Phase 2Unknown
- Sponsor
- GSK
- Start
- Aug 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of belantamab mafodotin in multiple myeloma (MM) (2 arms), sponsored by GSK. Primary endpoint: Dose escalation safety and tolerability. Status: unknown.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-004689-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004689-93.